OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule  pro-drug) and emerging Globo H science. OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab (PD-1) and the association of high Globo H and PD-L1 expression resulting in poor survival in gastric cancer […]